

Supporting Information

Efficient Direct Asymmetric Vinylogous Michael Addition Reactions of γ -Butenolides to Chalcones Catalyzed by Vicinal Primary-diamine Salts

Junfeng Wang, Chao Qi, Zemei Ge,* Tieming Cheng, Run-Tao Li*


*State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences,
Peking University, Beijing 100191, P. R. China*

lirt@mail.bjmu.edu.cn; zmge@bjmu.edu.cn

General Information


Unless otherwise stated, all reagents were purchased from commercial suppliers and were used without further purification. 2(5H)-Furanones **1** that were not commercially available were prepared in our lab from substituted phenacyl bromide¹. Reactions were monitored by thin layer chromatography (TLC) on GF₂₅₄ silica gel plates. ¹H NMR spectra and ¹³C NMR spectra were recorded on a JEOL JNM-AL300 (300 MHz) spectrometer in needful D-reagents with tetramethylsilane (TMS) as an internal reference. Data for ¹H NMR are reported as follows: chemical shift (ppm), and multiplicity (s = singlet, d = doublet, t = triplet, dd = double of doublet, br = broad, m = multiplet), coupling constants (Hz) and integration; Data for ¹³C NMR are reported as ppm. Melting points were measured on an X₄-type micro-melting point apparatus and were uncorrected. Elemental analyses were performed on a Vario EL III instrument. High-resolution mass spectra (HRMS) were obtained on a Bruker APEX IV FT_MS (7.0) spectrometer for electrospray ionization (ESI). HPLC analyses were performed using a Daicel ChiralPak AD column purchased. Crystal structure determination of the Michael product **3p** was carried out on a Bruker Smart Apex-II CCD diffractometer. Optical rotations were measured on a AA-10R automatic polarimeter and are reported as follows: $[\alpha]_D^{25}$ (*c* in g per 100 mL of solvent).

**Representative procedure for the synthesis of 2(5H)-Furanones 1:
Synthesis of 1a, 1c and 1d (Synthesis of 1a as the example):**



Phenacyl bromide **A1** (20.0 mmol) was added to a solution of phenylacetic acid **B** (20.0 mmol) in acetonitrile (30-50ml) containing sodium bicarbonate (24.0 mmol) at room temperature with stirring. The mixture was refluxed for the required time until the disappearance of **A** monitored by TLC (silica gel, pet ether: ethyl acetate, 4:1). The mixture was added NaOH 2.0-4.0 mmol and refluxed until the completion of the reaction by TLC (silica gel, pet ether: ethyl acetate, 4:1). The resulting mixture was filtered off through a short column of silica gel and washed with ethyl acetate and pet ether (pet ether: ethyl acetate, 2:1). The solvent from the filtrate was removed under reduced pressure and the solid residue was purified by recrystallisation (pet ether: ethyl acetate, 4:1) to afford the pure product **1a**.


Synthesis of 1b:



The substituted phenacyl bromide **A2** (20.0 mmol) was added to a solution of phenylacetic acid **B** (20.0 mmol) in acetonitrile (30-50ml) containing potassium carbonate (30.0 mmol) at room temperature with stirring. The mixture was refluxed for the required time monitored by TLC (silica gel, pet ether: ethyl acetate, 4:1). The resulting mixture was filtered off through a short column of silica gel and washed with ethyl acetate and pet ether (pet ether: ethyl acetate, 2:1). The solvent from the filtrate was removed under reduced pressure and the solid residue was purified by


recrystallisation (pet ether: ethyl acetate, 4:1) to afford the pure product **1b**.

Preparation for the racemic vinylogous Michael products:



To a mixture of **1a**, **1b**, **1c** or **1d** (0.5 mmol), a chalcone (0.6 mmol) and ethanediamine (0.1 mmol) in 2.0 ml of CH_2Cl_2 was added the acid additive (0.1 mmol of hexanedioic acid prepared in 1.0 ml of anhydrous CH_3OH). The mixture was refluxed for the required time monitored by TLC (silica gel, pet ether: ethyl acetate, 5:1) and then directly purified by filtration and/or preparative TLC chromatography to afford the pure products.



General procedure for vinylogous Michael reaction:



To a mixture of **1a**, **1b**, **1c** or **1d** (0.5 mmol), a chalcone (0.6 mmol) and chiral catalyst 1,2-diaminocyclohexane **V** or **VI** (0.1 mmol) in 0.8 ml of CH_2Cl_2 was added the acid additive (0.1 mmol of hexanedioic acid prepared in 0.4 ml of anhydrous CH_3OH). The resulting mixture was stirred under room temperature in dark for 6 days and then directly purified by filtration and/or preparative TLC chromatography to afford the pure products.

Optimization of Reaction Conditions:

Catalyst Screening




Entry	Cat. ^a	Additive ^a	Yield	dr ^d	ee (%) ^d
			(%) ^c		
1	I	-	N.R.	-	-
2	III	-	Trace	-	-
3	I	TEA	-	-	-
4	II	TEA	Trace	-	-
5	IV	AcOH	8	-	0
6	V	AcOH ^[b]	35	98:2	87
7	V	Hexanedioic acid	40	98:2	90
8	V	TfOH	trace	-	-
9	V	-	trace	-	-
10 ^e	V	Hexanedioic acid	69	>99:1	96

^aThe catalyst and additive loading was 20 mol%. ^bThe additive loading of HOAc was 40 mol%. ^cIsolated yield of the corresponding product.

^dDetermined by chiral-phase HPLC and/or ¹H NMR. ^e(1S, 2S)-1,2-diaminocyclohexane. ^fThe reaction was conducted at room temperature in dark for 6 days; solvent: CH₂Cl₂:MeOH = 2:1.

Acid Additive and Solvent Screening




Entry	Catalyst	Additive	Solvent	Time	Yield(%) ^a	dr (%) ^b	ee (%) ^b
1	V ^c	AcOH	MeOH	6days	35	>98:2	87
2	V	CF ₃ COOH	MeOH	6days	Trace	-	-
3	V	HO ₂ CCH ₂ CO ₂ H	MeOH	6days	37	>96:4	84
4	V	HO ₂ C(CH ₂) ₄ CO ₂ H	MeOH	6days	40	>98:2	90
5	V	HO ₂ C(CH ₂) ₄ CO ₂ H	EtOH	6days	28	90:10	86
6	V	HO ₂ C(CH ₂) ₄ CO ₂ H	CH ₂ Cl ₂	6days	-	-	-
7	V	HO ₂ C(CH ₂) ₄ CO ₂ H	CHCl ₃	6days	-	-	-
8	V	HO ₂ C(CH ₂) ₄ CO ₂ H	THF	6days	-	-	-
9	V	HO ₂ C(CH ₂) ₄ CO ₂ H	DMF	6days	-	-	-
10	V	HO ₂ C(CH ₂) ₄ CO ₂ H	DMSO	6days	-	-	-
11	V	HO ₂ C(CH ₂) ₄ CO ₂ H	PhCH ₃	6days	-	-	-
12	V	HO ₂ C(CH ₂) ₄ CO ₂ H	MeOH CH ₂ Cl ₂ ^d	7days	69	>99:1	96

^aIsolated yield of the corresponding product. ^bDetermined by chiral-phase HPLC and/or H NMR. ^c(1*S*, 2*S*)-1,2-diaminocyclohexane. ^dThe reaction was conducted at room temperature in dark for 6 days; solvent: CH₂Cl₂:MeOH = 2:1.

Scope of the vinylogous Michael addition reaction


5-(3-Oxo-1-phenyl-3-p-tolylpropyl)-3,4-diphenylfuran-2(5*H*)-one 3a: obtained in 69% yield; white powder; m.p. 210–211 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.95 (d, *J* = 7.8 Hz, 2H), 7.40 (m, 3H), 7.30–7.18 (m, 10H), 6.96–6.88 (d, 4H), 6.01 (d, *J* = 2.4 Hz, 1H), 4.09 (dd, *J* = 10.0 Hz, 18.0 Hz, 1H), 3.88–3.84 (m, 1H), 3.41 (dd, *J* = 4.0 Hz, 18.4 Hz, 1H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 198.2, 172.7, 158.9, 144.4, 136.5, 134.3, 130.7, 130.3, 130.0, 129.4, 128.9, 128.8, 128.8, 128.4, 128.4, 128.1, 128.0, 127.6, 127.5, 81.8, 42.5, 40.5, 21.6; Anal. Calcd for



= 7.8 Hz, 2H), 7.40 (m, 3H), 7.30–7.18 (m, 10H), 6.96–6.88 (d, 4H), 6.01 (d, *J* = 2.4 Hz, 1H), 4.09 (dd, *J* = 10.0 Hz, 18.0 Hz, 1H), 3.88–3.84 (m, 1H), 3.41 (dd, *J* = 4.0 Hz, 18.4 Hz, 1H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 198.2, 172.7, 158.9, 144.4, 136.5, 134.3, 130.7, 130.3, 130.0, 129.4, 128.9, 128.8, 128.8, 128.4, 128.4, 128.1, 128.0, 127.6, 127.5, 81.8, 42.5, 40.5, 21.6; Anal. Calcd for


$C_{32}H_{26}O_3$: C 83.82, H 5.72; found: C 83.68, H 5.68; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_R 10.47 min (major enantiomer), 12.87 min (minor enantiomer); dr >99:1; ee 96%; $[\alpha]_D^{25} = +39$ ($c = 1.0$, CHCl₃).

5-(3-Oxo-1,3-diphenylpropyl)-3,4-diphenylfuran-2(5*H*)-one 3b: Obtained in 65%




yield; white powder; 210-211°C; ¹H NMR (300 MHz, CDCl₃): δ 8.04 (d, $J = 7.8$ Hz, 2H), 7.61 (tri, $J = 6.6$ Hz, 1H), 7.51 (tri, $J = 7.2$ Hz, 2H), 7.41 (d, $J = 6.9$ Hz, 3H), 7.30-7.19 (m, 8H), 6.96-6.88 (m, 4H), 6.01 (s, 1H), 4.11 (dd, $J = 6.9$ Hz, 18.0 Hz, 1H), 3.88-3.85 (m, 1H), 3.44 (dd, $J = 3.9$ Hz, 18.0 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 198.5, 172.6, 158.8, 136.6, 136.3, 133.5, 130.6, 130.3, 129.9, 128.8, 128.7, 128.4, 128.0, 127.5, 81.7, 42.4, 40.6; Anal. Calcd for C₃₁H₂₄O₃: C 83.76, H 5.44; found: C 83.32, H 5.33; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_R 7.19 min (major enantiomer), 11.26 min (minor enantiomer); dr >93:7; ee 91%; $[\alpha]_D^{25} = +33$ ($c = 1.3$, CHCl₃).

5-[3-oxo-3-phenyl-1-(thiophen-2-yl)propyl]-3,4-diphenylfuran-2(5*H*)-one 3c1:




Obtained in 62% yield; white powder; 206-207°C; ¹H NMR (125 MHz, CDCl₃): δ 7.95 (d, $J = 8.0$ Hz, 2H), 7.50 (d, $J = 8.0$ Hz, 1H), 7.41 (d, $J = 4.0$ Hz, 1H), 7.32-7.22 (m, 8H), 7.16 (dd, $J = 3.6$ Hz, 8.4 Hz, 1H), 6.93 (d, $J = 6.4$ Hz, 4H), 5.97 (d, $J = 2.0$ Hz, 1H), 4.09 (dd, $J = 4.4$ Hz, 18.4 Hz, 1H), 3.82 (m, 1H), 3.42 (dd, $J = 3.6$ Hz, 18.4 Hz, 1H), 2.45 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 198.0, 171.9, 156.1, 144.5, 136.2, 134.6, 134.1, 133.4, 131.0, 130.6, 130.4, 129.4, 129.2, 129.1, 128.9, 128.8, 128.7, 128.2, 128.2, 127.9, 127.8, 81.5, 42.4, 40.4, 21.7; Anal. Calcd for C₂₉H₂₂O₃S: C 77.31, H 4.92; found: C 77.34, H 5.02; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_R 7.32 min (major enantiomer), 12.61 min (minor enantiomer); dr >99:1; ee 89%; $[\alpha]_D^{25} = +28$ ($c = 1.1$, CHCl₃); **3c2:** HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_R 7.29 min (minor enantiomer), 12.73 min (major enantiomer); dr >95:5; ee -91%; $[\alpha]_D^{25} = -30$ ($c = 1.3$, CHCl₃).

5-[3-oxo-1-(thiophen-2-yl)-3-p-tolylpropyl]-3,4-diphenylfuran-2(5H)-one 3d:




Obtained in 70% yield; white powder; 181-182°C; ^1H NMR (125 MHz, CDCl_3): δ 7.95 (d, $J = 8.0$ Hz, 2H), 7.44-7.38 (m, 3H), 7.36-7.34 (m, 2H), 7.32-7.26 (m, 2H), 7.16 (m, 1H), 7.11-7.08 (m, 2H), 6.87 (m, 1H), 6.56 (d, $J = 3.2$ Hz, 1H), 5.98 (d, $J = 2.4$ Hz, 1H), 4.24 (m, 1H), 4.00 (dd, $J = 10.4$ Hz, 18.0 Hz, 1H), 3.44 (dd, $J = 4.0$ Hz, 18.4 Hz, 1H), 2.44 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 197.7, 172.7, 158.7, 144.6, 138.4, 134.1, 129.5, 129.0, 128.9, 128.8, 128.5, 128.2, 127.9, 126.5, 126.3, 124.6, 81.2, 42.2, 38.2, 21.7; Anal. Calcd for $\text{C}_{30}\text{H}_{24}\text{O}_3\text{S}$: C 77.56, H 5.21; found: C 77.52, H 5.22; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_{R} 10.67 min (major enantiomer), 14.23 min (minor enantiomer); dr >99:1; ee 91%; $[\alpha]_{\text{D}}^{25} = +29$ ($c = 0.9$, CHCl_3).

5-(3-Oxo-3-phenyl-1-p-tolylpropyl)-3,4-diphenylfuran-2(5H)-one 3e: obtained in




61% yield; white powder; m.p. 192-193°C; ^1H NMR (300 MHz, CDCl_3): δ 8.04 (d, $J = 7.8$ Hz, 2H), 7.60 (tri, $J = 6.9$ Hz, 1H), 7.51 (tri, $J = 7.2$ Hz, 2H), 7.41 (d, $J = 6.9$ Hz, 3H), 7.31-6.98 (m, 5H), 7.01-6.98 (m, 4H), 6.78 (d, $J = 7.8$ Hz, 2H), 5.99 (s, 1H), 4.09 (dd, $J = 9.9$ Hz, 18.3 Hz, 1H), 3.85-3.81 (m, 1H), 3.42 (dd, $J = 3.3$ Hz, 18.3 Hz, 1H), 2.29 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ 198.6, 172.7, 159.0, 137.1, 136.7, 133.5, 133.3, 130.7, 130.3, 130.0, 128.9, 128.7, 128.4, 128.0, 127.5, 81.8, 42.0, 40.8, 21.0; Anal. Calcd for $\text{C}_{32}\text{H}_{26}\text{O}_3$: C 83.82, H 5.72; found: C 83.62, H 5.66; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_{R} 7.46 min (major enantiomer), 12.55 min (minor enantiomer); dr 96:4; ee 94%; $[\alpha]_{\text{D}}^{25} = +37$ ($c = 1.2$, CHCl_3).



5-[3-(3-Nitrophenyl)-3-oxo-1-(thiophen-2-yl)propyl]-3,4-diphenylfuran-2(5H)-one 3f: obtained in 36% yield; white powder; m.p. 206-207°C; ^1H NMR (300 MHz, CDCl_3): δ 8.85 (s, 1H), 8.47 (d, $J = 6.9$ Hz, 1H), 8.35 (d, $J = 6.6$ Hz, 1H), 7.74 (tri, $J = 7.5$ Hz, 1H), 7.42 (d, $J = 5.7$ Hz, 2H), 7.32-7.26


(m, 3H), 7.17 (d, $J = 4.8$ Hz, 2H), 7.09 (m, 2H), 6.86 (m, 1H), 6.54 (s, 1H), 5.96 (s, 1H), 4.21 (m, 1H), 4.06 (dd, $J = 9.6$ Hz, 18.3 Hz, 1H), 3.55 (dd, $J = 4.2$ Hz, 18.3 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3): δ 195.8, 172.4, 158.3, 148.4, 137.5, 133.5, 130.4, 130.2, 130.1, 129.7, 128.8, 128.6, 128.5, 128.4, 127.8, 126.6, 126.4, 124.8, 122.9, 80.9, 42.6, 37.9; Anal. Calcd for $\text{C}_{29}\text{H}_{21}\text{NO}_5\text{S}$: C 70.29, H 4.27, N 2.83; found: C 70.24, H 4.29, N 2.85; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_{R} 11.29 min (major enantiomer), 32.51 min (minor enantiomer); dr 93:6; ee 96%; $[\alpha]_D^{25} = +62$ ($c = 0.9$, CHCl_3).

5-(1-(2-Chlorophenyl)-3-oxo-3-phenylpropyl)-3,4-diphenylfuran-2(5H)-one 3g:



obtained in 63% yield; white powder; m.p. 179-180 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.03 (d, $J = 7.2$ Hz, 2H), 7.62-7.47 (m, 4H), 7.40-7.30 (m, 3H), 7.28-7.22 (m, 6H), 7.14-7.12 (m, 2H), 7.08-7.05 (m, 2H), 6.17 (d, $J = 3.2$ Hz, 1H), 4.65-4.61 (m, 1H), 4.04 (dd, $J = 10.0$ Hz, 18.4 Hz, 1H), 3.33 (dd, $J = 4.4$ Hz, 18.4 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 197.9, 172.7, 159.2, 136.5, 135.1, 134.3, 133.5, 130.7, 130.3, 129.9, 129.6, 129.3, 128.9, 128.8, 128.7, 128.6, 128.4, 128.4, 128.0, 127.3, 126.7, 81.7, 41.2, 37.3; Anal. Calcd for $\text{C}_{31}\text{H}_{23}\text{ClO}_3$: C 77.74, H 4.84; found: C 77.61, H 4.79; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_{R} 6.83 min (major enantiomer), 9.02 min (minor enantiomer); dr >99:1; ee 80%; $[\alpha]_D^{25} = +33$ ($c = 1.0$, CHCl_3).


4-[3,4-Dichlorophenyl]-5-(3-oxo-1,3-diphenylpropyl)-3-phenylfuran-2(5H)-one



3h: obtained in 66% yield; white powder; m.p. 209-210 °C; ^1H NMR (300 MHz, CDCl_3): δ 8.04 (d, $J = 8.4$ Hz, 2H), 7.62 (tri, $J = 7.5$ Hz, 1H), 7.51 (tri, $J = 9.0$ Hz, 3H), 7.39 (d, $J = 1.5$ Hz, 1H), 7.28-7.22 (m, 6H), 7.14 (dd, $J = 1.5$ Hz, 8.4 Hz, 1H), 6.92 (d, $J = 6.0$ Hz, 4H), 5.96 (d, $J = 1.8$ Hz, 1H), 4.11 (dd, $J = 10.2$ Hz, 18.6 Hz, 1H), 3.84-3.81 (m, 1H), 3.44 (dd, $J = 3.3$ Hz, 18.3 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3): δ 198.4, 171.9, 156.0, 136.5, 136.1, 134.6, 133.6, 133.4, 131.0, 130.6, 130.4,


130.3, 129.1, 128.9, 128.7, 128.7, 128.2, 128.0, 127.9, 81.4, 42.4, 40.5; Anal. Calcd for C₃₁H₂₂Cl₂O₃: C 72.52, H 4.32; found: C 72.33, H 4.25; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_R 9.07 min (major enantiomer), 15.13 min (minor enantiomer); dr 98:2; ee 95%; [α]_D²⁵ = +40 (c = 1.1, CHCl₃).

4-(3,4-dichlorophenyl)-5-[3-oxo-3-phenyl-1-(thiophen-2-yl)propyl]-3-phenylfuran



-2(5H)-one 3i: Obtained in 71% yield; white powder; 194-195°C; ¹H NMR (400 MHz, CDCl₃): δ 8.04 (d, J = 7.6 Hz, 2H), 7.63 (tri, J = 8.0 Hz, 1H), 7.54-7.46 (m, 4H), 7.33-7.27 (m, 3H), 7.21-7.18 (m, 2H), 7.08-7.05 (m, 2H), 6.90 (m, 1H), 6.62 (d, J = 3.2 Hz, 1H), 5.93 (d, J = 2.0 Hz, 1H), 4.19 (dd, J = 2.8 Hz, 7.6 Hz, 1H), 4.06 (dd, J = 10.0 Hz, 18.0 Hz, 1H), 3.47 (dd, J = 4.4 Hz, 18.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 197.9, 171.9, 155.7, 137.9, 134.7, 133.8, 133.4, 131.0, 130.4, 129.4, 129.2, 129.1, 128.8, 128.8, 128.1, 128.0, 126.6, 126.6, 124.8, 80.9, 42.2, 38.0; Anal. Calcd for C₂₉H₂₀Cl₂O₃S·0.3H₂O: C 66.36, H 3.96; found: C 66.52, H 3.92; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_R 8.63 min (major enantiomer), 17.48 min (minor enantiomer); dr = 97:3; ee 95%; [α]_D²⁵ = +37 (c = 1.3, CHCl₃).


4-(3,4-dichlorophenyl)-5-[3-oxo-1-(thiophen-2-yl)-3-*p*-tolylpropyl]-3-phenylfuran



-2(5H)-one 3j: Obtained in 74% yield; white powder; 221-223°C; ¹H NMR (125 MHz, CDCl₃): δ 7.94 (d, J = 8.0 Hz, 2H), 7.48 (tri, J = 8.0 Hz, 1H), 7.32-7.29 (m, 5H), 7.21-7.18 (m, 2H), 7.07-7.05 (m, 2H), 6.90 (m, 1H), 6.62 (d, J = 2.8 Hz, 1H), 5.92 (d, J = 2.0 Hz, 1H), 4.19 (m, 1H), 4.03 (dd, J = 10.0 Hz, 18.0 Hz, 1H), 3.43 (dd, J = 3.6 Hz, 18.4 Hz, 1H), 2.45 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 197.6, 171.9, 155.7, 144.7, 137.9, 129.5, 129.4, 129.2, 129.0, 128.8, 128.7, 128.2, 128.0, 126.6, 126.5, 124.8, 80.9, 42.0, 38.0, 21.7, 1.03; Anal. Calcd for C₃₀H₂₂Cl₂O₃S·0.3H₂O: C 66.87, H 4.23; found: C 66.86, H 4.18; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_R 15.64 min (major enantiomer),


18.63 min (minor enantiomer); dr >99:1; ee 91%; $[\alpha]_D^{25} = +35$ ($c = 1.0$, CHCl₃).

4-(3,4-dichlorophenyl)-5-[3-oxo-1-phenyl-3-p-tolylpropyl]-3-phenylfuran-2(5H)-one 3k1:



ne 3k1: Obtained in 75% yield; white powder; 205-206 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.95 (d, $J = 8.4$ Hz, 2H), 7.51 (d, $J = 8.0$ Hz, 1H), 7.41 (m, 1H), 7.32-7.21 (m, 8H), 6.93 (dd, $J = 1.6$ Hz, 6.4 Hz, 1H), 5.96 (d, $J = 2.4$ Hz, 1H), 4.09 (dd, $J = 10.4$ Hz, 18.4 Hz, 1H), 3.81 (m, 1H), 3.42 (dd, $J = 3.6$ Hz, 18.0 Hz, 1H), 2.45 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 198.0, 172.0, 156.1, 144.5, 131.0, 130.4, 129.5, 129.2, 129.2, 128.9, 128.8, 128.7, 128.3, 128.2, 128.0, 127.9, 81.5, 42.5, 40.4, 21.7, 1.04; Anal. Calcd for C₃₂H₂₄Cl₂O₃·0.3H₂O: C 72.13, H 4.65; found: C 72.11, H 4.61; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_R 10.93 min (major enantiomer), 12.23 min (minor enantiomer); dr >99:1; ee 96%; $[\alpha]_D^{25} = +35$ ($c = 1.0$, CHCl₃); **3k2:** HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_R 10.06 min (minor enantiomer), 12.25 min (major enantiomer); dr >99:1; ee -95%; $[\alpha]_D^{25} = -33$ ($c = 1.2$, CHCl₃).

4-(3,4-Dichlorophenyl)-5-(3-oxo-3-phenyl-1-p-tolylpropyl)-3-phenylfuran-2(5H)-one 3l:



one 3l: obtained in 69% yield; white powder; m.p. 203-204 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.04 (d, $J = 7.5$ Hz, 2H), 7.61 (tri, $J = 7.5$ Hz, 1H), 7.51 (tri, $J = 8.1$ Hz, 3H), 7.41 (s, 1H), 7.27 (d, $J = 6.6$ Hz, 3H), 7.15 (d, $J = 8.4$ Hz, 1H), 7.03 (d, $J = 7.5$ Hz, 2H), 6.95 (d, $J = 6.9$ Hz, 2H), 6.81 (d, $J = 7.5$ Hz, 2H), 5.93 (s, 1H), 4.07 (dd, $J = 9.9$ Hz, 18.3 Hz, 1H), 3.79 (d, $J = 9.9$ Hz, 1H), 3.41 (d, $J = 18.3$ Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 198.5, 172.0, 156.1, 137.5, 136.6, 134.6, 133.6, 133.4, 133.0, 131.0, 130.7, 130.4, 129.2, 129.0, 128.9, 128.7, 128.6, 128.0, 127.9, 81.6, 42.0, 40.7, 21.0; Anal. Calcd for C₃₂H₂₄Cl₂O₃: C 72.87, H 4.59; found: C 72.65, H 4.70; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_R 10.00 min (major enantiomer), 17.44 min (minor enantiomer); dr >99:1; ee 96%; $[\alpha]_D^{25} = +43$ ($c = 1.0$, CHCl₃).


5-(1-(4-Chlorophenyl)-3-oxo-3-phenylpropyl)-4-(3,4-dichlorophenyl)-3-phenylfur an-2(5H)-one 3m:

Obtained in 78% yield; white powder; 180–182 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.04 (d, $J = 7.2$ Hz, 2H), 7.51 (tri, $J = 6.6$ Hz, 1H), 7.63 (m, 1H), 7.54–7.49 (m, 3H), 7.44 (m, 1H), 7.31–7.27 (m, 3H), 7.22 (m, 2H), 7.14 (m, 1H), 6.98 (m, 2H), 6.88 (d, $J = 8.4$ Hz, 2H), 5.93 (d, $J = 2.0$ Hz, 1H), 4.05 (dd, $J = 10.0$ Hz, 15.6 Hz, 1H), 3.82 (m, 1H), 3.42 (dd, $J = 4.0$ Hz, 15.6 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 198.1, 171.7, 155.8, 133.8, 131.1, 130.5, 130.3, 130.1, 129.3, 129.1, 129.0, 128.8, 128.8, 128.7, 128.5, 128.1, 127.9, 81.3, 41.8, 40.6; Anal. Calcd for $\text{C}_{31}\text{H}_{21}\text{Cl}_3\text{O}_3 \cdot 0.3\text{H}_2\text{O}$: C 67.30, H 3.94; found: C 67.53, H 3.91; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_{R} 10.21 min (major enantiomer), 21.53 min (minor enantiomer); dr = 91:9; ee 92%; $[\alpha]_D^{25} = +31$ ($c = 1.4$, CHCl_3).

5-(1-(3-Chlorophenyl)-3-oxo-3-phenylpropyl)-4-(3,4-dichlorophenyl)-3-phenylfur an-2(5H)-one 3n:



obtained in 78% yield; white powder; m.p. 181–182 °C; ^1H NMR (300 MHz, CDCl_3): δ 8.04 (d, $J = 7.8$ Hz, 2H), 7.63 (tri, $J = 7.5$ Hz, 1H), 7.52 (tri, $J = 7.5$ Hz, 3H), 7.40 (s, 1H), 7.29–7.21 (m, 5H), 7.17 (d, $J = 7.8$ Hz, 1H), 6.98 (d, $J = 7.2$ Hz, 2H), 6.90 (d, $J = 7.2$ Hz, 1H), 6.83 (s, 1H), 5.92 (s, 1H), 4.06 (dd, $J = 7.2$ Hz, 18.3 Hz, 1H), 3.81–3.78 (m, 1H), 3.45 (dd, $J = 3.9$ Hz, 18.3 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3): δ 197.9, 171.6, 155.8, 138.1, 136.3, 134.8, 134.0, 133.7, 133.6, 131.1, 130.5, 130.3, 130.2, 129.5, 129.2, 129.1, 129.0, 128.8, 128.7, 128.7, 128.0, 127.9, 127.8, 126.6, 81.1, 42.0, 40.2; Anal. Calcd for $\text{C}_{31}\text{H}_{22}\text{Cl}_3\text{O}_3$: C 67.96, H 3.86; found: C 67.77, H 3.80; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_{R} 8.36 min (major enantiomer), 16.70 min (minor enantiomer); dr >95:5; ee 91%; $[\alpha]_D^{25} = +32$ ($c = 1.2$, CHCl_3).

5-(1-(2-Chlorophenyl)-3-oxo-3-phenylpropyl)-4-(3,4-dichlorophenyl)-3-phenylfur-2(5H)-one 3o:



an-2(5H)-one 3o: obtained in 73% yield; white powder; m.p. 184-185°C; ^1H NMR (300 MHz, CDCl_3): δ 7.80 (d, $J = 7.5$ Hz, 2H), 7.56 (tri, $J = 7.2$ Hz, 1H), overlapping with 7.50 (d, $J = 7.5$ Hz, 1H), 7.45-7.33 (m, 8H), 7.26-7.18 (m, 4H), 7.10 (dd, $J = 1.5$ Hz, 8.1 Hz, 1H), 5.67 (d, $J = 2.7$ Hz, 1H), 4.43 (m, 1H), 3.46 (dd, $J = 8.4$ Hz, 15.4 Hz, 1H), 3.24 (dd, $J = 5.4$ Hz, 15.4 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3): δ 196.1, 171.4, 155.9, 137.6, 136.1, 134.7, 133.5, 133.4, 133.3, 130.8, 130.1, 130.0, 130.0, 129.8, 129.3, 129.2, 129.1, 129.0, 128.7, 127.9, 127.6, 127.3, 82.7, 38.9, 35.9; Anal. Calcd for $\text{C}_{31}\text{H}_{21}\text{Cl}_3\text{O}_3$: C 67.96, H 3.86; found: C 67.78, H 3.76; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_{R} 9.66 min (major enantiomer), 13.18 min (minor enantiomer); dr >98:2; ee 83%; $[\alpha]_{\text{D}}^{25} = +44$ ($c = 1.3$, CHCl_3).


4-(4-Methoxyphenyl)-5-(3-oxo-3-phenyl-1-(thiophen-2-yl)propyl)-3-phenylfuran-2(5H)-one 3p:



Obtained in 37% yield; white powder; m.p. 178-180°C; ^1H NMR (300 MHz, CDCl_3): δ 8.05 (d, $J = 7.2$ Hz, 2H), 7.62 (tri, $J = 7.2$ Hz, 1H), 7.51 (tri, $J = 7.5$ Hz, 2H), 7.35-7.26 (m, 5H), 7.16 (d, $J = 3.9$ Hz, 1H), 7.08-7.04 (m, 2H), 6.94-6.86 (m, 3H), 6.57 (d, $J = 3.3$ Hz, 1H), 5.93 (d, $J = 2.4$ Hz, 1H), 4.26-4.23 (m, 1H), 4.10 (dd, $J = 10.2$ Hz, 18.3 Hz, 1H), 3.86 (s, 3H), 3.46 (dd, $J = 3.6$ Hz, 18.3 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 198.3, 172.9, 161.2, 158.3, 138.2, 136.4, 133.7, 130.4, 130.3, 128.9, 128.8, 128.5, 128.3, 128.1, 126.4, 126.3, 125.9, 124.5, 122.7, 114.3, 80.9, 55.3, 42.2, 38.3; HRMS-ESI (m/z): $[(\text{M}+\text{Na})^+]$ calcd. for $\text{C}_{17}\text{H}_{22}\text{O}_7\text{Na}$ 503.1293, found 503.1298; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_{R} 10.79 min (major)


enantiomer), 19.54 min (minor enantiomer); dr >99:1; ee 92%; $[\alpha]_D^{25} = +12.7$ ($c = 0.6$, CHCl_3); HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_R 11.53 min (major enantiomer), 22.07 min (minor enantiomer); dr >99:1; ee 92%; $[\alpha]_D^{25} = -12.3$ ($c = 0.7$, CHCl_3).

4-(3,4-Fimethoxyphenyl)-5-(3-oxo-1-phenyl-3-p-tolylpropyl)-3-phenylfuran-2(5H)-one 3q: obtained in 46% yield; white powder; m.p. 200-201 °C; ^1H NMR (300 MHz,



CDCl_3): δ 7.96 (d, $J = 7.8$ Hz, 2H), 7.32-7.15 (m, 9H), 6.96-6.88 (m, 5H), 6.69 (s, 1H), 5.96 (s, 1H), 4.16 (dd, $J = 10.8$ Hz, 18.3 Hz, 1H), 3.99-3.95 (m, 1H) overlapping with 3.95 (s, 3H), 3.59 (s, 3H), 3.37 (dd, $J = 3.0$ Hz, 18.3 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 198.4, 172.9, 158.7, 150.8, 148.8, 144.4, 136.6, 134.3, 130.8, 129.4, 129.0, 129.0, 128.5, 128.2, 128.2, 128.0, 128.6, 126.0, 123.2, 122.1, 111.8, 111.1, 81.5, 55.9, 55.5, 42.9, 40.3, 21.7; Anal. Calcd for $\text{C}_{34}\text{H}_{35}\text{O}_5$: C 78.74, H 5.83; found: C 78.53, H 5.85; HPLC (AD, hexane:*i*-PrOH 50:50, 1.0 mL/min): t_R 9.16 min (major enantiomer), 10.78 min (minor enantiomer); dr 98:2; ee 95%; $[\alpha]_D^{25} = +43$ ($c = 0.9$, CHCl_3).

5-(3-oxo-1-phenyl-3-p-tolylpropyl)furan-2(5H)-one 3r: obtained in 67% yield;





colorless oil; ^1H NMR (500 MHz, CDCl_3): δ 7.88 (d, $J = 8.0$ Hz, 2.52H), 7.78 (d, $J = 8.0$ Hz, 4.85H); 7.36-7.31 (m, 11.2H), 7.29-7.19 (m, 18.5H), 6.07 (dd, $J = 2.0$ Hz, 5.5 Hz, 2.01H), 5.85 (dd, $J = 2.0$ Hz, 5.5 Hz, 1.00H), 5.45 (p, $J = 1.5$ Hz, 1.14H), 3.27-2.26 (m, 2.38H); 3.97-3.94 (m, 1.28H), 3.78 (dd, $J = 8.0$ Hz, 17.5 Hz, 1.43H), 3.73-3.68 (m, 2.60H); 3.56-3.51 (m, 2.79H); 3.46-3.40 (m, 3.95H); 2.41 (s, 3.91H); 7.36 (s, 7.36); ^{13}C NMR (125 MHz, CDCl_3): δ 197.4, 196.9, 172.7, 155.6, 155.3, 144.4, 144.2, 139.8, 137.3, 134.1, 129.4, 129.3, 128.9, 128.6, 128.4, 128.2, 128.1, 128.1, 127.6, 122.1, 121.9, 85.8, 84.4, 44.3, 43.0, 40.0, 39.8, 29.7, 21.7, 21.6.

Reference:



1. A. Zarghi et al. *Bioorg. Med. Chem.* **2007**, *15*, 1056.

NMR spectra for Michael product 3


3a




3b





3d




3e





3f




3g




3h




3i








3k




31




3m




3n




3o



3p



3q



3r



wf09092708

File: PROTON
Pulse Sequence: s2pul
Solvent: cdc13
Temp. 25.0 C / 298.1
TNOVA-500 "BMRU500"

```

Relax. delay 4.000 sec
Pulse 85.3 degrees
Acq. time 1.892 sec
Width 7998.4 Hz
16 repetitions
OBSERVE H1 499.9018999 H
DATA PROCESSING
FT size 65536
Total time 1 min, 34 sec

```



wf09092708



File: CARBON
Pulse Sequence: s2pul
Solvent: cdc13
Temp. 25.0 °C / 298.1 K
User: 1-14-87

```

INDVA-500 "BMU500"


Relax, delay 1.000 sec
Pulse 45.0 degrees
Ave. time 1.300 sec
Width 31421.8 Hz
1440 repetitions
OBSERVE C13, 125.7004346
DECODIFY H1, 499.9043861
Power 38 dB
continuously on
WALTZ-16 modulated
DATA PROCESSING
Line broadening 3.0 Hz
FT size 131072
Total time 16 hr. 25 min.

```




HPLC Analyses for Michael product 3



3a




Injection Date : 1/15/2009 9:55:07 AM
Sample Name : wf09011301
Acq. Operator : MOVY
Acq. Method : C:\HPCHEM\1\METHODS\YG.M
Last changed : 1/15/2009 9:25:50 AM bv liujm
(modified after loading)




3b




3c





3c1





3c2





3d



3e




3f




3g

Injection Date : 1/12/2009 4:56:12 PM
Sample Name : wf09010908re
Acq. Operator : MOVY
Acq. Method : C:\HPCHEM\1\METHODS\YG.M
Last changed : 1/12/2009 1:22:16 PM bv MOVY
(modified after loading)




Injection Date : 1/12/2009 5:19:24 PM
Sample Name : wf09010908
Acq. Operator : MOVY
Acq. Method : C:\HPCHEM\1\METHODS\YG.M
Last changed : 1/12/2009 1:22:16 PM bv MOVY
(modified after loading)




3h



Injection Date : 1/8/2009 4:37:51 PM
Sample Name : wf09010407
Acq. Operator : MOVY
Acq. Method : C:\HPCHEM\1\METHODS\YG.M
Last changed : 1/8/2009 4:01:34 PM bv MOVY





Injection Date : 1/8/2009 2:58:44 PM
Sample Name : wf09010602
Acq. Operator : MOVY
Acq. Method : C:\HPCHEM\1\METHODS\YG.M
Last changed : 1/8/2009 2:22:19 PM bv Linshi
(modified after loading)




3i




3j




3k



3k1




3k2




31



Injection Date : 1/9/2009 10:43:37 AM
 Sample Name : wf09010603re
 Acq. Operator : MOVY
 Acq. Method : C:\HPCHEM\1\METHODS\YG.M
 Last changed : 1/9/2009 9:56:07 AM bv MOVY



Injection Date : 1/12/2009 9:46:34 AM
 Sample Name : wf09010603
 Acq. Operator : MOVY
 Acq. Method : C:\HPCHEM\1\METHODS\YG.M
 Last changed : 1/12/2009 9:20:28 AM bv MOVY
 (modified after loading)




3m




3n

Injection Date : 1/12/2009 6:06:45 PM
 Sample Name : wf09010904re
 Acq. Operator : MOVY
 Acq. Method : C:\HPCHEM\1\METHODS\YG.M
 Last changed : 1/12/2009 1:22:16 PM bv MOVY
(modified after loading)




Injection Date : 1/12/2009 6:36:44 PM
 Sample Name : wf09010904
 Acq. Operator : MOVY
 Acq. Method : C:\HPCHEM\1\METHODS\YG.M
 Last changed : 1/12/2009 1:22:16 PM bv MOVY
(modified after loading)



30

Injection Date : 1/12/2009 5:36:00 PM
Sample Name : wf09010903re
Acq. Operator : MOVY
Acq. Method : C:\HPCHEM\1\METHODS\YG.M
Last changed : 1/12/2009 1:22:16 PM bv MOVY

(modified after loading)



DAD1 E, Sig=310,16 Ref=360,100 (MOVY\MOVY0410.D)

mAU

Chemical structure of a chiral compound:

CC(C(=O)c1ccc(Cl)c(Cl)c1)[C@H]2[C@H](C2)C(=O)c3ccccc3Cl


Peaks:

Retention Time (min)	Peak Type	Wavelength (nm)	Intensity
9.660	PP	0.3200	4063.18848
11.859	BP	0.3852	100.28519
13.183	BP	0.5040	426.55075


=====
Injection Date : 1/12/2009 5:51:07 PM
Sample Name : wf09010903
Acq. Operator : MOVY
Acq. Method : C:\HPCHEM\1\METHODS\YG.M
Last changed : 1/12/2009 1:22:16 PM bv MOVY

3p

Injection Date : 12/22/2008 6:38:49 PM
Sample Name : wf08121610re
Acq. Operator : MOVY
Acq. Method : C:\HPCHEM\1\METHODS\YG.M
Last changed : 12/22/2008 3:28:33 PM by MOVY
(modified after loading)




Injection Date : 12/22/2008 4:45:43 PM
Sample Name : wf08121609
Acq. Operator : MOVY
Acq. Method : C:\HPCHEM\1\METHODS\YG.M
Last changed : 12/22/2008 3:28:33 PM by MOVY
(modified after loading)




3q

Injection Date : 1/8/2009 2:27:58 PM
Sample Name : wf09010801
Acq. Operator : MOVY
Acq. Method : C:\HPCHEM\1\METHODS\YG.M
Last changed : 1/8/2009 2:22:19 PM by Linshi
(modified after loading)




Injection Date : 1/8/2009 4:05:09 PM
Sample Name : wf09010406
Acq. Operator : MOVY
Acq. Method : C:\HPCHEM\1\METHODS\YG.M
Last changed : 1/8/2009 4:01:34 PM by MOVY




1 9.168 BBA 0.2760 2002.28528 113.37322 97.4822
2 10.789 BBA 0.3136 51.71552 2.53897 2.5178

3r


Injection Date : 9/22/2009 10:16:22 AM
Sample Name : wf09091804-re
Acq. Operator : MOVY
Acq. Method : C:\HPCHEM\1\METHODS\YG.M
Last changed : 9/22/2009 10:12:33 AM by MOVY



Injection Date : 9/22/2009 10:55:02 AM
Sample Name : wf09091608
Acq. Operator : MOVY
Acq. Method : C:\HPCHEM\1\METHODS\YG.M
Last changed : 9/22/2009 10:12:33 AM by MOVY



CD Spectra of **3p**



Date 2010-1-21 9:58
File name Memory#2
Model J-810
Serial No. B038360750
Band width 2 nm
Response 1 sec
Sensitivity Standard
Measurement range 400 - 250 nm
Data pitch 1nm
Scanning speed 200 nm/min
Accumulation 5
Cell Length 1 cm
Solvent CDCl₃
Temperature Room Temperature

Sample name 3p
Operator jfwang
Comment